Earnings ·
Evotec reports preliminary nine-month revenue of €465M, reaffirms full-year guidance
EVOEvotec SE
Evotec announced preliminary unaudited financial results for the first nine months of 2026. The company expects Group revenues of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures exceed current market expectations, primarily due to the phasing of consensus estimates. Evotec reaffirmed its full-year 2026 guidance, projecting Group revenues between €570 million and €610 million (or €595 million to €635 million at constant exchange rates) and adjusted Group EBITDA between -€70 million and -€105 million (-€60 million to -€90 million at CER). Full financial results for the third quarter and the first nine months will be published on November 5, 2026. Evotec operates in the life sciences sector, providing drug discovery and development services.